STX-478, a Mutant-Selective, Allosteric PI3Kα Inhibitor Spares Metabolic Dysfunction and Improves Therapeutic Response in PI3Kα-Mutant Xenografts

Leonard Buckbinder(Scorpion Therapeutics (United States)), Darrin D. Stuart(Scorpion Therapeutics (United States))

Cancer Discovery

August 25, 2023

10.1158/2159-8290.cd-23-0396

Cited by 67

Related Papers

No related papers found

Powered by citation graph analysis